More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$135145871
P/E ratio
14.6
Dividend yield
2.1372%
Expense ratio
0.75%
Beta
1.132187
Previous close
$27.02
Today's open
$27.47
Day's range
$26.61 - $28.04
52 week range
$16.50 - $46.75
Equities
Multi Alternative
49.05%
TLRY
Tilray Inc
14.18%
CRON:CA
Cronos Group Inc.
8.41%
WEED:CA
Canopy Growth Corporation
6.96%
SNDL:CA
Sundial Growers Inc
6.08%
5.57%
ACB:CA
Aurora Cannabis Inc
3.53%
HITI:CA
High Tide Inc
3.39%
OGI:CA
Organigram Holdings Inc
2.35%
0.34%
Marijuana Stocks to Watch Before the Next Cannabis Rally
The cannabis sector continues to attract investors seeking long-term growth opportunities in 2026. Although volatility remains high, many marijuana companies are improving operations and cutting costs. At the same time, investors continue watching potential federal reform closely. Rescheduling discussions and banking reform could become major catalysts for the industry.

3 Top Picks For Marijuana Stocks Investors To See Profits In 2026
For marijuana stock investors, the way the industry as a whole progresses determines a great deal for them. For example, no one wants to invest in a struggling industry even if it's been trendy along the way. Now, cannabis has fallen to that path, but it's also what's making this industry one of the hottest sectors in the last 5 years. Legal cannabis has been a long uphill battle in every sense. Legislation and regulatory issues remain the biggest challenges.

Trump's Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs
After amassing enormous losses over the past five years, cannabis stocks received a much-needed shot in the arm last week when President Donald Trump announced plans to officially reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
MarketBeat • May 3, 2026

Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets, providing a lifeline to the struggling cannabis industry.
Reuters • Apr 30, 2026

Cannabis ETFs: Regulatory Momentum Returns Focus
Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.
ETF Trends • Apr 30, 2026

Top U.S. Marijuana Stocks to Watch in April 2026 as the Sector Heats Up
The U.S. cannabis sector continues showing strong long-term growth potential in 2026. The legal market continues to expand across multiple states. In fact, the industry is projected to grow significantly over the next decade. Additionally, more states continue moving toward legalization in some form.

Cannabis Stocks Soared—Than Sank. Here's What Investors Need to Know.
Marijuana-related investments were flying high this morning. Then they reversed course, and quickly.
Investopedia • Apr 23, 2026

Amplify ETFs Offer Unique Angles on Income, Thematics
The rise of Amplify ETFs is one of the more interesting stories in the U.S. ETF industry. Although it only launched its first ETF under that brand in 2016, its founder, Christian Magoon, was a well-known figure in the ETF space long before that.
ETF Trends • Apr 17, 2026

Why MJ Is No Longer A Sell
Amplify Alternative Harvest ETF is upgraded from Sell to Hold after a 33% decline, reflecting improved valuation but persistent sector risks. MJ's structure remains highly concentrated, with over half in CNBS and significant exposure to MSOs and Canadian LPs, driving volatility. Key upside catalysts include potential 280E tax elimination and Canadian cultivation tax reform, but regulatory uncertainty remains high.
Seeking Alpha • Feb 20, 2026

Trump signs executive order to reschedule cannabis. Here's what's next
Trump's executive order shifts cannabis from Schedule I to Schedule III, and launches a Medicare pilot program for CBD products. Brandon Gomez unpacks what's next, the hurdles ahead and what shifted the President's stance on the drug.
CNBC Television • Dec 19, 2025

¹ Disclosures

Open an M1 investment account to buy and sell ETFMG Alternative Harvest ETF commission-free¹. Build wealth for the long term using automated trading and transfers.